https://pbs.twimg.com/media/FhhS8ulWYAAiR0W.jpg
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s

Links:

Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selec… https://acrabstracts.org/abstract/baseline-biomarkers-predict-better-responses-…
Richard Conway
RichardPAConway
14-11-2022
×